Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 clinical trial to determine safety, tolerability, pharmacokinetics, and pharmacodynamics of AZP-3813 in healthy subjects

Next Previous
X
Search
Trial Profile

Phase 1 clinical trial to determine safety, tolerability, pharmacokinetics, and pharmacodynamics of AZP-3813 in healthy subjects

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 02 Aug 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AZP-3813 (Primary)
  • Indications Acromegaly
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Sponsors Amolyt Pharma

    • Most Recent Events

    • 15 Jul 2024 According to an Amolyt Pharma media release, Amolyt Pharma has been acquired AstraZeneca.
    • 07 May 2024 According to an Amolyt Pharma media release, abstracts accepted for assessing safety, tolerability, pharmacokinetics and pharmacodynamics of AZP-3813 from this trial at the 2024 Endocrine Society Meeting (ENDO), which is being held June 1-4 in Boston, Massachusetts.
    • 07 May 2024 According to an Amolyt Pharma media release, abstracts accepted for assessing safety, tolerability, pharmacokinetics and pharmacodynamics of AZP-3813 from this trial at the 26th European Congress of Endocrinology (ECE), which is being held May 11-14 in Stockholm, Sweden.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top